Merck & Co., Inc. on January 31, 2020 announcing the election of Kathy J. Warden and Christine E. Seidman, M.D. to the Company’s Board of Directors, effective March 16, 2020. The Board appointed each of Ms. Warden and Dr. Seidman as a member of both the Audit Committee and the Research Committee of the Board. For their service on the Board, Ms. Warden and Dr. Seidman will receive compensation as non-employee directors in accordance with the Company’s non-employee director compensation practices described under the “Director Compensation” section of the Company’s definitive proxy statement on Schedule 14A filed with the Securities and Exchange Commission on April 8, 2019. Dr. Seidman is the Thomas W. Smith Professor of Medicine and Genetics at Harvard Medical School and is the director of the Cardiovascular Genetics Program at Brigham and Women’s Hospital. She leads a research laboratory that focuses on integrating clinical medicine and molecular technologies to define disease-causing gene mutations and genetic variations that increase disease risk. Dr. Seidman was awarded the Vanderbilt Prize in Biomedical Sciences in 2018 and elected to the National Academy of Sciences in 2005. She earned her degree in biochemistry from Harvard University, her M.D. from The George Washington University and completed her residency in internal medicine at Johns Hopkins University.